ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism. (4th August 2021)

• Record Type: Journal Article
• Authors: Bhatt, Mihir D.; Portman, Michael A.; Berger, Felix; Jacobs, Jeffrey P.; Newburger, Jane; Duggal, Anil; Grosso, Michael; Pandya, Grishma; Dave, Jay; Goldenberg, Neil A.
• Is Part Of: Cardiology in the young. Volume 31:Number 8(2021)
• Page Start: 1213
• Page End: 1219
• Publication Date: 2021-08-04
• Subjects: Paediatrics -- anticoagulation -- congenital heart disease -- Kawasaki disease -- edoxaban -- direct oral anticoagulant; Pediatric cardiology -- Periodicals; 618.9212
• DOI: 10.1017/S1047951121002523
• Languages: English
• ISSNs: 1047-9511

Abstract

Abstract: Children with cardiac diseases suffer from significant morbidity and mortality secondary to thromboembolic complications. Anticoagulant agents currently used for thromboprophylaxis have many limitations, including subcutaneous administration (low molecular weight heparins) and requirement for frequent monitoring via venipuncture (vitamin K antagonists). Edoxaban is an oral direct factor Xa inhibitor without need of monitoring. In the treatment of venous thromboembolism in adults, edoxaban has shown to be effective and safe. This manuscript summarises the rationale and design of a phase 3, open-label, randomised controlled trial to evaluate and compare the safety and efficacy of edoxaban against standard of care (namely, vitamin K antagonist and low molecular weight heparin) in children with cardiac diseases. A goal of 150 children with cardiac diseases at risk of thromboembolic complications who need primary or secondary anticoagulant prophylaxis will be recruited. Eligible children between 6 months and <18 years of age will be randomised in a ratio of 2 to 1 for edoxaban versus standard of care. Randomisation will be stratified based on underlying cardiac disease and concomitant use of aspirin for patients other than Kawasaki disease. The primary outcome will be safety, comprised of major and clinically relevant non-major bleeding in first 3 months of treatment. Bleeding beyond 3 months, symptomatic and asymptomatic thromboembolic events, and pharmacokinetic and pharmacodynamic parameters will be evaluated as secondary outcomes. Randomised controlled anticoagulation trials are challenging in children. This study will evaluate a potentially valuable alternative of oral anticoagulant prophylactic use in children with cardiac diseases.